USD10
KYTX Ações
Sobre Kyverna TherapeuticsKyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
USD10
KYTX Ações
Sobre Kyverna TherapeuticsKyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Estatísticas
JANELA DE NEGOCIAÇÃO
Fechado
ABRE ÀS
31 de mar. at 13:30 GMT+0
CAPITALIZAÇÃO DE MERCADO
US$ 456,04 mi
PREÇO ABERTO
Sem dados suficientes
BAIXO (1 A)
US$ 1,78
ALTO (1 A)
US$ 13,67
BAIXO (24H)
US$ 7,35
ALTO (24H)
US$ 8,16
VOLUME (24H)
US$ 373,13 mil
703.919,47%
Histórico de preços
Time | Price | Change |
|---|---|---|
Hoje | Sem dados suficientes | Sem dados suficientes |
1 dia | US$ 8,02 | |
1 semana | US$ 7,68 | |
1 mês | US$ 8,31 | |
1 ano | US$ 1,98 |